Cargando…

TransDTI: Transformer-Based Language Models for Estimating DTIs and Building a Drug Recommendation Workflow

[Image: see text] The identification of novel drug–target interactions is a labor-intensive and low-throughput process. In silico alternatives have proved to be of immense importance in assisting the drug discovery process. Here, we present TransDTI, a multiclass classification and regression workfl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalakoti, Yogesh, Yadav, Shashank, Sundar, Durai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8792915/
https://www.ncbi.nlm.nih.gov/pubmed/35097268
http://dx.doi.org/10.1021/acsomega.1c05203
_version_ 1784640484146151424
author Kalakoti, Yogesh
Yadav, Shashank
Sundar, Durai
author_facet Kalakoti, Yogesh
Yadav, Shashank
Sundar, Durai
author_sort Kalakoti, Yogesh
collection PubMed
description [Image: see text] The identification of novel drug–target interactions is a labor-intensive and low-throughput process. In silico alternatives have proved to be of immense importance in assisting the drug discovery process. Here, we present TransDTI, a multiclass classification and regression workflow employing transformer-based language models to segregate interactions between drug–target pairs as active, inactive, and intermediate. The models were trained with large-scale drug–target interaction (DTI) data sets, which reported an improvement in performance in terms of the area under receiver operating characteristic (auROC), the area under precision recall (auPR), Matthew’s correlation coefficient (MCC), and R2 over baseline methods. The results showed that models based on transformer-based language models effectively predict novel drug–target interactions from sequence data. The proposed models significantly outperformed existing methods like DeepConvDTI, DeepDTA, and DeepDTI on a test data set. Further, the validity of novel interactions predicted by TransDTI was found to be backed by molecular docking and simulation analysis, where the model prediction had similar or better interaction potential for MAP2k and transforming growth factor-β (TGFβ) and their known inhibitors. Proposed approaches can have a significant impact on the development of personalized therapy and clinical decision making.
format Online
Article
Text
id pubmed-8792915
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-87929152022-01-28 TransDTI: Transformer-Based Language Models for Estimating DTIs and Building a Drug Recommendation Workflow Kalakoti, Yogesh Yadav, Shashank Sundar, Durai ACS Omega [Image: see text] The identification of novel drug–target interactions is a labor-intensive and low-throughput process. In silico alternatives have proved to be of immense importance in assisting the drug discovery process. Here, we present TransDTI, a multiclass classification and regression workflow employing transformer-based language models to segregate interactions between drug–target pairs as active, inactive, and intermediate. The models were trained with large-scale drug–target interaction (DTI) data sets, which reported an improvement in performance in terms of the area under receiver operating characteristic (auROC), the area under precision recall (auPR), Matthew’s correlation coefficient (MCC), and R2 over baseline methods. The results showed that models based on transformer-based language models effectively predict novel drug–target interactions from sequence data. The proposed models significantly outperformed existing methods like DeepConvDTI, DeepDTA, and DeepDTI on a test data set. Further, the validity of novel interactions predicted by TransDTI was found to be backed by molecular docking and simulation analysis, where the model prediction had similar or better interaction potential for MAP2k and transforming growth factor-β (TGFβ) and their known inhibitors. Proposed approaches can have a significant impact on the development of personalized therapy and clinical decision making. American Chemical Society 2022-01-12 /pmc/articles/PMC8792915/ /pubmed/35097268 http://dx.doi.org/10.1021/acsomega.1c05203 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Kalakoti, Yogesh
Yadav, Shashank
Sundar, Durai
TransDTI: Transformer-Based Language Models for Estimating DTIs and Building a Drug Recommendation Workflow
title TransDTI: Transformer-Based Language Models for Estimating DTIs and Building a Drug Recommendation Workflow
title_full TransDTI: Transformer-Based Language Models for Estimating DTIs and Building a Drug Recommendation Workflow
title_fullStr TransDTI: Transformer-Based Language Models for Estimating DTIs and Building a Drug Recommendation Workflow
title_full_unstemmed TransDTI: Transformer-Based Language Models for Estimating DTIs and Building a Drug Recommendation Workflow
title_short TransDTI: Transformer-Based Language Models for Estimating DTIs and Building a Drug Recommendation Workflow
title_sort transdti: transformer-based language models for estimating dtis and building a drug recommendation workflow
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8792915/
https://www.ncbi.nlm.nih.gov/pubmed/35097268
http://dx.doi.org/10.1021/acsomega.1c05203
work_keys_str_mv AT kalakotiyogesh transdtitransformerbasedlanguagemodelsforestimatingdtisandbuildingadrugrecommendationworkflow
AT yadavshashank transdtitransformerbasedlanguagemodelsforestimatingdtisandbuildingadrugrecommendationworkflow
AT sundardurai transdtitransformerbasedlanguagemodelsforestimatingdtisandbuildingadrugrecommendationworkflow